As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here.
On paper, biotech had quite a year in 2018.
Futuristic medicines demonstrated their worth in clinical trials and now look poised to become revolutionary therapies. Scrappy upstarts developed novel drugs without the need for their pharma forebears. And investors were game to fund the whole endeavor, buying into initial public offerings that kept the industry churning.
About the Author Reprints
From “Is there demand ..,” in defense of Moderna (New Years resolution – “Be Kind”), one may observe that a retreating tide lowers all boats as well. It will be instructive to see where both MRNA nad the NASDAQ are at the end of Q1 and Q2.